Topoisomerase II inhibitors

Update on Cancer Therapeutics

Volumn 3, Issue 1, 2008, Pages 13-26

  Hande, Kenneth R ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Anthracyclines; Chemotherapy; Etoposide; Pharmacology; Topoisomerase II

Indexed keywords

2,3 BIS(3,5 DIOXO 1 PIPERAZINYL)BUTANE; 6 [2 (DIMETHYLAMINO)ETHYLAMINO] 3 HYDROXY 7H INDENO[2,1 C]QUINOLIN 7 ONE; ANTHRACYCLINE; ANTHRACYCLINE DERIVATIVE; ANTIHISTAMINIC AGENT; CARBOPLATIN; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DAUNORUBICIN; DAUNORUBICINOL; DOXORUBICIN; DOXORUBICINOL; ELACRIDAR; EPIPODOPHYLLOTOXIN DERIVATIVE; EPIRUBICIN; ETOPOFOS; ETOPOSIDE; F 11782; GYRASE INHIBITOR; IDARUBICIN; IFOSFAMIDE; MITOXANTRONE; PACLITAXEL; PHENOBARBITAL; PHENYTOIN; PNU 159548; PREDNISONE; RAZOXANE; TENIPOSIDE; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALSPODAR; VINCRISTINE; XR 5000;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ALOPECIA; ANAL CANAL; ANUS PRURITUS; AREA UNDER THE CURVE; BLADDER CANCER; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER CHEMOTHERAPY; CARDIOMYOPATHY; CARDIOTOXICITY; CENTRAL NERVOUS SYSTEM TUMOR; CHILL; CHROMOSOME CONDENSATION; CHROMOSOME SEGREGATION; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTINUOUS INFUSION; CYTOTOXICITY; DIFFUSE FOLLICULAR RASH; DNA REPLICATION; DRUG BIOAVAILABILITY; DRUG DOSE COMPARISON; DRUG ERUPTION; DRUG FORMULATION; DRUG HYPERSENSITIVITY; FEVER; GERM CELL TUMOR; GLIOMA; HAND FOOT SYNDROME; HEART ARRHYTHMIA; HEART INJURY; HUMAN; HYPERSENSITIVITY REACTION; INTERTRIGO LIKE ERUPTION; KAPOSI SARCOMA; LEUKEMIA; LIVER TOXICITY; LUNG CANCER; LUNG SMALL CELL CANCER; LUNG TOXICITY; LYMPHOMA; MELANOTIC MACULE; MUCOSA INFLAMMATION; NAUSEA; NEUROBLASTOMA; NONHODGKIN LYMPHOMA; NONHUMAN; OVARY CANCER; PERICARDITIS; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROSTATE CANCER; REVIEW; SARCOMA; SIDE EFFECT; SKIN TOXICITY; SOFT TISSUE SARCOMA; TESTIS CANCER; TISSUE REACTION; VASOMOTOR DISORDER; VOMITING;

EID: 40949114287     PISSN: 1872115X     EISSN: 1872115X     Source Type: Journal    
DOI: 10.1016/j.uct.2008.02.001     Document Type: Review

References (205)

1. Champous J.J. DNA topoisomerases: structure function and mechanism. Annu Rev Biochem 70 (2001) 369-413
2. Wang J.C. Cellular roles of DNA topoisomerases: a molecular perspective. Nat Rev Mol Cell Biol 3 (2002) 430-440
3. Kellner U., Sehested M., Jensen P.B., Gieseler F., and Rudolph P. Culprit and victim-DNA topoisomerase II. Lancet Oncol 3 (2002) 235-243
4. Watt P.M., and Hickson I.D. Structure and function of type II DNA topoisomerases. Biochem J 303 (1994) 681-695
5. Fortune J.M., and Osheroff N. Topoisomerase II as a target for anticancer drugs: when enzymes stop being nice. Proc Nucleic Acid Res Mol Biol 64 (2000) 221-253
6. Gatto B., and Leo E. Drugs acting on the beta isoform of human topoisomerase II. Curr Med Chem 3 (2003) 175-185
7. Bromberg K.D., Burgin A.B., and Osheroff N. A two-drug model for etoposide action against human topoisomerase II alpha. J Biol Chem 278 (2003) 7406-7412
8. Montecucco A., and Biamonti G. Cellular response to etoposide treatment. Cancer Lett 252 (2007) 9-18
9. Robertson J.D., Enoksson M., Suomela M., Zhivotovsky B., and Orrenius S. Caspase 2 acts upstream of mitochondria to promote cytochrome C release during etoposide-induced apoptosis. J Biol Chem 277 (2002) 29803-29809
10. Lin C.F., Chen C.L., Chang W.T., Jan M.S., Hsu L.L., and Wu R.H. Sequential caspase-2 and caspase-8 activation of mitochondria during ceramide and etoposide induced apoptosis. J Biol Chem 279 (2004) 40755-40761
11. Yang X.H., Sladek T.L., Liu X., Butler B.R., Froelich C.J., and Thor A.D. Reconstitution of caspase 3 sensitizes MCF-7 breast cancer cells to doxorubicin- and etoposide-induced apoptosis. Cancer Res 61 (2001) 348-354
12. Filomenko R., Prevolat L., Rebe C., Cortier M., Jeannin J.F., Solary E., et al. Caspase 10 involvement in cytotoxic drug-induced apoptosis of tumor cells. Oncogene 25 (2006) 7635-7645
13. Singh T.R., Shankar S., Chen X., Asim M., and Srivastava R.K. Synergistic interactions of chemotherapeutic drugs and tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand on apoptosis and on regression of breast carcinoma in vivo. Cancer Res 63 (2003) 5390-5400
14. Miao L., Yi P., Wang Y., and Wu M. Etoposide up regulates Bax-enhancing tumor necrosis factor-related apoptosis inducing ligand-mediated apoptosis in the human hepatocellular carcinoma cell line QGY-7703. Eur J Biochem 270 (2003) 2721-2731
15. Tao W., Hangoc G., Hawes J.W., Si Y., Cooper S., and Broxmeyer H.E. Profiling of differentially expressed apoptosis-related genes by cDNA arrays in human cord blood CD34+ cells treated with etoposide. Exp Hematol 31 (2003) 251-260
16. Clifford B., Beljin M., Stark G.R., and Taylor W.R. G2 arrest in response to topoisomerase II inhibitors: the role of p53. Cancer Res 63 (2003) 4074-4081
17. Nakada S., Katsuki Y., Imoto I., Yokoyama T., Nagasawa M., Inazawa J., et al. Early G2/M checkpoint failure as a molecular mechanism underlying etoposide-induced chromosomal aberrations. J Clin Invest 116 (2006) 80-90
18. Chikamori K., Grabowski D.R., Kinter M., Willard B.B., Yadav S., Aebersold R.H., et al. Phosphorylation of serine 1106 in the catalytic domain of topoisomerase II alpha regulates enzymatic activity and drug sensitivity. J Biol Chem 278 (2003) 12696-12702
19. Adachi N., Suzuki H., Iiizumi S., and Koyama H. Hypersensitivity of nonhomologous DNA end-joining mutants to VP-16 and ICRF-193: implications for the repair of topoisomerase II-mediated DNA damage. J Biol Chem 278 (2003) 35897-35902
20. Yao Q., Weigel B., and Kersey J. Synergism between etoposide and 17-AAG in leukemic cells: critical roles for Hsp90, FLT3, topoisomerase II, Chk1 and Rad51. Clin Cancer Res 13 (2007) 1591-1600
21. Schroeder U., Bernt K.M., Lange B., Wenkel J., Jikai J., Shabat D., et al. Hydrolytically activated etoposide prodrugs inhibit MDR-1 function and eradicate established MDR-1 multidrug-resistant T-cell leukemia. Blood 102 (2003) 246-253
22. Marigny K., Aubin F., Burgot G., Le Gall E., and Gandemar V. Particular cutaneous side effects with etoposide-containing courses: is VP-16 or etoposide phosphate responsible?. Cancer Chemother Pharmacol 55 (2005) 244-250
23. Hotelmans R.M., Schornagel J.H., ten Bokkel Huinink W.W., and Beijnan J.H. Hypersensitivity reactions to etoposide. Ann Pharmacother 30 (1996) 367-371
24. Thompson D.S., Greco A., Miller A.A., Srinivas N.R., Igwemezie K.B., Hainsworth J.D., et al. A phase I study of etoposide phosphate administered as a daily 30-minute infusion for 5 days. Clin Pharmacol Ther 57 (1995) 499-507
25. Siderov J., Prasad P., DeBoer R., and Desai J. Safe administration of etoposide phosphate after hypersensitivity reaction to intravenous etoposide. Br J Cancer 86 (2002) 12-13
26. Dorr R.T., Briggs A., Kintzel P., Meyers H., Chow H.S., and List A. Comparative pharmacokinetic study of high-dose etoposide and etoposide phosphate in patients with lymphoid malignancy receiving autologous stem cell transplantation. Bone Marrow Transplant 31 (2003) 643-649
27. Pui C.H. Epipodophyllotoxin-related acute myeloid. Lancet 338 (1991) 1468
28. Smith M.A., Rubenstein L., Anderson J.R., Arthur D., Catalano P.J., Friedlin B., et al. Secondary leukemia or myelodysplastic syndrome after treatment with intravenous epipodophyllotoxins. J Clin Oncol 17 (1999) 569-577
29. Anonymous. DNA topoisomerase II inhibitors. IARC Monographs on the evaluation of carcinogenic risk to humans, vol. 76; 2000. p. 175-344.
30. Pedersen-Bjergaard J., Sigsgaard T.C., Nielsen D., Gjedde S.B., Phillip P., Hansen M., et al. Acute monocytic or myelomonocytic leukemia with balanced chromosome translocations to band 11q23 after therapy with 4-epi-doxorubicin and cisplatin or cyclophosphamide for breast cancer. J Clin Oncol 10 (1992) 1444-1451
31. Sandoval C., Pui C.H., Bowman L.C., Heaton D., Hurwitz C.A., Raimondi S.C., et al. Secondary acute myeloid leukemia in children previously treated with alkylating agents, intercalating topoisomerase II inhibitors, and irradiation. J Clin Oncol 11 (1993) 1039-1045
32. Ahuja H.G., Felxi C.A., and Aplan P.D. Potential role for DNA topoisomerase II poisons in the generation of t(11:20)(p15;q11) translocations. Genes Chromosomes Cancer 29 (2000) 96-105
33. Strissel P.L., Strick R., Rowley J.D., and Zeleznik-Le N.J. An in vitro topoisomerase II cleavage site and a DNase hypersensitivity site in t(8,21) leukaemia. Proc Natl Acad Sci 99 (1998) 3070-3075
34. Blanco J.G., Edick M.J., and Reiling M.V. Etoposide induces chimeric Mll gene fusions. FASEB J 18 (2004) 1173-1175
35. Ng A., Taylor G.M., and Eden O.B. Genotoxicity of etoposide: greater susceptibility of MLL than other target genes. Cancer Genetics Cytogen 164 (2006) 164-167
36. Sung P.A., Libura A., and Richardson C. Etoposide and illegitimate DNA double-strand break repair in the generation of MLL translocations: new insights and new questions. DNA Repair 5 (2006) 1109-1118
37. Lovett B.D., Strumberg D., Blair I.A., Pang S., Burden D.A., Megonigal M.D., et al. Etoposide metabolites enhance DNA topoisomerase II cleavage near leukemia-associated MLL translocation breakpoints. Biochemistry 40 (2001) 1159-1170
38. Lovett B.D., Lo Nigro L., Rappaport E.F., Blair I.A., Osharoff N., Zeng N., et al. Near-precise interchromosomal recombination and functional DNA topoisomerase II cleavage sites in MLL and AF-4 genomic breakpoints in treatment-related acute lymphoblastic leukemia with t(4:11) translocation. Proc Natl Acad Sci 98 (2001) 9802-9807
39. Hars E.S., Lyu Y.L., Lin C.P., and Liu L.F. Role of apoptotic nuclease caspase-activated DNase in etoposide-induced treatment related leukemia. Caner Res 66 (2006) 8975-8979
40. Monneypenny C.G.S., Shao J., Song Y., and Gallagher E.P. MLL rearrangements are induced by low doses of etoposide in human fetal hematopoietic stem cells. Carcinogenesis 27 (2006) 874-881
41. Smith M.A., Rubinstein L., Anderson J.R., Arthur D., Catalano P.J., Freidlin B., et al. Secondary leukemia or myelodysplastic syndrome after treatment with epipodophyllotoxins. J Clin Oncol 17 (1999) 569-577
42. Houck W., Abonour R., Vance G., and Einhorn L.H. Secondary leukemia in refractory germ cell tumor patients undergoing autologous stem cell transplantation using high dose etoposide. J Clin Oncol 22 (2004) 2155-2158
43. Le Deley M.C., Leblanc T., Shamsaldin A., Raquin M.A., Lacour B., Sommelet D., et al. Risk of secondary leukemia after a solid tumor in childhood according to the dose of epipodophyllotoxins and anthracyclines: a case-control study by the Society Francaise d'Oncologie Pediatrique. J Clin Oncol 21 (2003) 1074-1081
44. Sugita K., Furukawa T., Tsuchida M., et al. High frequency of etoposide (VP-16)-related secondary leukemia in children with non-Hodgkin's lymphoma. Am J Pediatr Hematol Oncol 15 (1993) 99-104
45. Winick N.J., McKenna R.W., Shuster J.J., Schneider N.R., Borowitz M.J., Bowman W.P., et al. Secondary acute myeloid leukemia in children with acute lymphoblastic leukemia treated with etoposide. J Clin Oncol 11 (1993) 209-217
46. Felix C.A., Walker A.H., Lange B.J., Williams T.M., Winick N.J., Cheng N.R.V., et al. Association of CYP3A4 genotype with treatment-related leukaemia. Proc Natl Acad Sci USA 95 (1998) 13176-13181
47. Woo M.H., Shuster J.J., Chen C., Bash R.O., Behm F.G., Camitta B., et al. Glutathione S-transferase genotypes in children who develop treatment-related acute myeloid malignancies. Leukemia 14 (2000) 232-237
48. Relling M.V., Yanishevski Y., Nemec J., Evans W.E., Boyett J.M., Behm F.G., et al. Etoposide and antimetabolite pharmacology in patients who develop secondary acute myeloid leukemia. Leukemia 12 (1998) 346-352
49. Krynetskaia N.F., Cai X., Nitiss J.L., Krynetski E.W., and Relling M.V. Thioguanine substitution alters DNA cleavage mediated by topoisomerase II. FASEB J 14 (2000) 2339-2344
50. Pui C.H., Relling M.V., Rivera G.K., Hancock M.L., Raimondi S.C., Heslop H.E., et al. Epipodophyllotoxin-related acute myeloid leukemia: a study of 35 cases. Leukemia 9 (1995) 1990-1996
51. Veal G.J., Errington J., Thomas H.D., Boddy A.W., and Lowis S. Biliary excretion of etoposide in children with cancer. Cancer Chemother Pharmacol 58 (2006) 415-417
52. D'Incalci M., Rossi C., Zucchetti M., Urso R., Cavalli F., Mangioni C., et al. Pharmacokinetics of etoposide in patients with abnormal renal and hepatic function. Cancer Res 46 (1986) 2566-2571
53. Hande K.R., Wolff S.N., Greco F.A., Hainsworth J.D., Reed G., and Johnson D.H. Etoposide kinetics in patients with obstructive jaundice. J Clin Oncol 8 (1990) 1101-1107
54. Wen Z, Tallman MN, Ali SY, Smith PC. UDP-glucuronosyltransferase 1A1 is the principal enzyme responsible for etoposide glucuronidation in the human liver and intestinal microsomes: structural characterization of phenolic and alcoholic glucuronides of etoposide and estimation of enzyme kinetics. Drug Metab Dispos 2007;35:371-80.
55. Zheng N., Felix C.A., Pang S., Boston R., Moate P., Scavuzzo J., et al. Plasma etoposide catechol increases in pediatric patients undergoing multiple day chemotherapy with etoposide. Clin Cancer Res 10 (2004) 2977-2985
56. Freyer G., Tranchand B., Ligneau B., Ardiet C., Souquet P.J., Court-Fortune I., et al. Population pharmacokinetics of doxorubicin, etoposide and ifosfamide in small cell lung cancer patients: results of a multicentre study. Br J Clin Pharmacol 50 (2000) 315-324
57. Thomas H.D., Porter D.J., Bartelinks I., Nobbs J.R., Cole M., Elliott S., et al. Randomized crossover clinical trial to study potential pharmacokinetic interactions between cisplatin or carboplatin and etoposide. Br J Clin Pharmacol 53 (2002) 83-91
58. Reif S., Nicolson M.C., Bisset D., Reid M., Kloft C., Jaehde U., et al. Effect of grapefruit juice intake on etoposide bioavailability. Eur J Clin Pharmacol 58 (2002) 491-494
59. Kishi S., Yang W., Boareau B., Morand S., Das S., Chen P., et al. Effects of prednisone and genetic polymorphisms on etoposide disposition in children with acute lymphoblastic leukemia. Blood 103 (2004) 67-72
60. Lum B.L., Kaubisch S., Fisher G.A., Brown B.W., and Sikic B.I. Effect of high-dose cyclosporine on etoposide pharmacodynamics in a trial to reverse P-glycoprotein (MDR1 gene) mediated drug resistance. Cancer Chemother Pharmacol 45 (2000) 305-311
61. Liu W.M., and Joel S.P. The schedule-dependent effects of etoposide in leukaemic cell lines: a function of concentration and duration. Cancer Chemother Pharmacol 51 (2003) 291-296
62. Slevin M.L., Clark P.I., Joel S.P., Malik S., Osborne R.J., Gregory W.M., et al. A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer. J Clin Oncol 7 (1989) 1333-1340
63. Toffoli G., Corona G., Basso B., and Boiocchi M. Pharmacokinetic optimization of treatment with oral etoposide. Clin Pharmacokinet 43 (2004) 441-466
64. Hande K.R., Krozely M.G., Greco F.A., Hainsworth J.D., Johnson D.H., and Greco F.A. Bioavailability of low-dose oral etoposide. J Clin Oncol 11 (1993) 374-377
65. Garcia-Lopez P., Coll M., Cervera E., Reyes-Vermot L., Torres M.A., Abrego-Perez G., et al. The systemic absorption of etoposide after intervaginal administration in patients with cervical intraepithelial lesions with human papillomavirus infection. Pharmaceutical Res 23 (2006) 378-383
66. Hande K.R., Messenger M., Wagner J., Krozely M., and Kaul S. Inter and intra-patient variability in etoposide kinetics with oral and intravenous drug administration. Clin Cancer Res 5 (1999) 2742-2747
67. Kato Y., Nishimura S., Sakura N., and Ueda K. Pharmacokinetics of etoposide with intravenous drug administration in children and adolescents. Pediatr Int 45 (2003) 74-79
68. Palle J., Britt-Marie F., Goran D., Merit H., Jukka K., Eva L., et al. Etoposide pharmacokinetics in children treated for acute myelogenous leukemia. Anti-Cancer Drugs 17 (2006) 1087-1094
69. Hande K.R. Etoposide: four decades of development of a topoisomerase II inhibitor. Eur J Cancer 34 (1998) 1514-1521
70. Edick M.J., Gajjar A., Mahmoud M., van de Poll M.E., Harrison P.L., Panetta J.C., et al. Pharmacokinetics and pharmacodynamics of oral etoposide in children with relapsed or refractory acute lymphoblastic leukemia. J Clin Oncol 21 (2003) 1340-1346
71. Braybrooke J.P., Levitt N.C., Joel S., Davis T., Madhusudan S., Tarley H., et al. Pharmacokinetic study of cisplatin and infusional etoposide phosphate in advanced breast cancer with correlation of response to topoisomerase II alpha expression. Clin Cancer Res 9 (2003) 4682-4688
72. Pfeundschuh M., Trumper L., Kloess M., Schmits R., Schmits R., Fellrr A.C., et al. Two-weekly or 3-weekly CHOP with or without etoposide for the treatment of young patients with good prognosis aggressive lymphomas: results of NHL-B1 trial of the DSHINIL. Blood 104 (2004) 626-633
73. Frost B.M., Forestier E., Gustafsson G., Nygen P., Hellebostad M., Jomsson O.G., et al. Translation t(12:21) is related to in vitro cellular drug sensitivity to doxorubicin and etoposide in childhood acute lymphocytic leukemia. Blood 104 (2004) 2452-2457
74. Xiao H., Mao Y., Desai S.D., Zhou N., Ting C.Y., Hwang J., et al. The topoisomerase II beta circular clamp arrests transcription and signals a 26S proteasome pathway. Proc Natl Acad Sci 100 (2003) 3239-3244
75. Lambert J.M., and Fernandez D.J. Topoisomerase II cleavable complex formation within DNA loop domains. Biochem Pharmacol 60 (2000) 101-109
76. Zhou R., Wang Y., Gruber A., Larson R., Castranos-Velez E., Lillemark E., et al. Topoisomerase II-mediated alterations of K562 drug resistant sub lines. Med Oncol 16 (1999) 191-198
77. Felix C.A. Leukemias related to treatment with DNA topoisomerase II inhibitors. Med Pediatr Oncol 36 (2001) 525-535
78. Stahelin H.F., and von Wartburg A. The chemical and biological route from podophyllotoxin glucoside to etoposide: ninth Cain memorial Award lecture. Cancer Res 51 (1991) 5-15
79. Toffoli G., Aita P., Sorio R., Corona G., Bertola A., Colassi A.H., et al. Effect of cyclosporin A on protein binding of teniposide in cancer patients. Anticancer Drugs 10 (1999) 511-518
80. Baker D.K., Relling M.V., Pui C.H., Christensen H.L., Evans W.C., and Rodman J.H. Increased teniposide clearance with concomitant anticonvulsant therapy. J Clin Oncol 10 (1992) 311-315
81. Relling M.V., Pui C.H., Sandlund J.T., Rivera G.K., Hancock M.L., Boyett J.M., et al. Adverse effect of anticonvulsants on efficacy of chemotherapy for acute lymphoblastic leukaemia. Lancet 356 (2000) 285-290
82. Vecht C.J., Wagner G.L., and Wilms E.B. Interactions between antiepileptic and chemotherapeutic drugs. Lancet Neurol 2 (2003) 404-409
83. Muggia F.M. Teniposide: overview of its therapeutic potential in adult cancers. Cancer Chemother Pharmacol 34 Suppl. (1994) S127-S133
84. Ettinger D.S., Finkelstein D.M., Ritch P.S., Lincoln S.T., and Blum R.H. Study of either ifosfamide or teniposide compared to a standard chemotherapy for extensive disease small cell lung cancer: an Eastern Cooperative Oncology Group randomized study. Lung Cancer 37 (2002) 311-318
85. Postmus P.E., Haaxma-Reiche H., Smit E.F., Groen H.J., Karnicka H., Lewinski T., et al. Treatment of brain metastases of small-cell lung cancer: comparing teniposide and teniposide with whole-brain radiotherapy-a phase III study of the European Organization for the Research and Treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol 18 (2000) 3400-3408
86. Weller M., Muller B., Koch R., Bamberg M., and Kransneck P. Neuro-Oncology Working Group 01 trial of nimustine plus teniposide versus nimustine plus cytarabine chemotherapy in addition to involved-field radiotherapy in the first-line treatment of malignant glioma. J Clin Oncol 21 (2003) 3276-3284
87. Tewey K.M., Rowe T.C., Yang L., Halligan B.D., and Liu L.F. Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. Science 226 (1984) 466-468
88. Swift L.P., Rephaeli A., Nudelman A., Phillips D.R., and Cutts S.M. Doxorubicin-DNA adducts induce a non-topoisomerase II mediated form of cell death. Cancer Res 66 (2006) 4863-4871
89. Bachur N.R., Yu F., Johnson R., Hickey R., Wu Y., and Malkas L. Helicase inhibition by anthracycline anticancer agents. Mol Pharmacol 41 (1992) 993-998
90. Mizutani H., Tada-Oikawa S., Hiraku Y., Koljima M., and Kawanishi S. Mechanism of apoptosis induced by doxorubicin through the generation of hydrogen peroxide. Life Sci 76 (2005) 1439-1453
91. Ashikawa K., Shishodia S., Fokt I., Priebe W., and Aggarwal B.B. Evidence that activation of nuclear factor-kappa B is essential for the cytotoxic effect of doxorubicin and its analogs. Biochem Pharmacol 67 (2004) 353-364
92. Bien S., Ritter C.A., Gratz M., Sperker B., Sonnemann J., Beck J.F., et al. Nuclear factor-kappa B mediates up-regulation of cathepsin B by doxorubicin in tumor cells. Mol Pharmacol 65 (2004) 1092-1102
93. Laurent G., and Jeffrezou J.P. Signaling pathways activated by daunorubicin. Blood 98 (2001) 913-924
94. Lorenzo E., Ruiz-Ruiz C., Quesada A.J., Hernandez G., Rodriguez A., Lopes-Rivas A., et al. Doxorubicin induces apoptosis and CD59 gene expression in human primary endothelial cells through a p53-dependent mechanism. J Biol Chem 277 (2002) 10833-10892
95. Tang Jj, Shen C., and Lu Y.J. Requirements for pre-existing p21 to prevent doxorubicin-induced apoptosis through inhibition of caspase-3 activation. Mol Cell Biochem 291 (2006) 139-144
96. Lee Y.K., Thomas S.N., Yang A.J., and Ann D.K. Doxorubicin down-regulates Kruppel-associated box domain-associated protein 1 sumoylation that relieves its transcription repression on p21WAF1/CIP1 in breast cancer MCF-7 cells. J Biol Chem 282 (2007) 1595-1606
97. Dorr R., Karanes C., Spier C., Grogan T., Greer J., Moore J., et al. Phase I/II study of the P-glycoprotein modulator PSC 833 in patients with acute myeloid leukemia. J Clin Oncol 19 (2001) 1589-1599
98. Planting A.S., Sonneveld P., van der Gaast A., Sparreboom A., van der Burg M.E., Luyton G.P., et al. A phase I and pharmacologic study of the MDR converter GF120918 in combination with doxorubicin in patients with advanced solid tumors. Cancer Chemother Pharmacol 55 (2005) 91-99
99. Tabe Y., Konopleva M., Contractor R., Munsell M., Shober W.D., Jin L., et al. Up regulation of MDR1 and induction of doxorubicin resistance by histone deacetylase inhibitor depsipeptide (FK228) and ATRA in acute promyelocytic leukemia cells. Blood 107 (2006) 1546-1554
100. Riganti C., Miraglia E., Costamanga C., Pescarmona G., Ghigo D., and Bosia A. Nitric oxide reverts the resistance to doxorubicin in human colon cancer cells by inhibiting the drug efflux. Cancer Res 65 (2005) 516-525
101. Puhlmann U., Ziemann C., Ruedell G., Vorwek H., Schaefer D., Langebrake C., et al. Impact of the cyclooxygenase system on doxorubicin-induced functional multidrug resistance 1 overexpression and doxorubicin sensitivity in acute myeloid leukemia HL-60 cells. J Pharmacol Exp Ther 312 (2005) 346-354
102. Kalyanaraman B., Joseph J., Kalivendi S., Wang S., Konorev E., and Kotamaju S. Doxorubicin-induced apoptosis: implications in cardiotoxicity. Mol Cell Biochem 234 (2002) 119-124
103. Kaiservova H., den Hartog G.J., Simunek T., Schroterova L., Kvasnickova E., and Bast A. Iron is not involved in oxidative-stress mediated cytotoxicity of doxorubicin. Br J Pharmacol 149 (2006) 920-930
104. Woodley-Cook J., Sin L.Y., Swystun L., Caruso S., Beaudin S., and Liaw P.C. Effects of the chemotherapeutic agent doxorubicin on the protein C anticoagulant pathway. Mol Cancer Ther 5 (2006) 3303-3311
105. Danesi R., Fogli S., Gennari A., Conte P., and del Tacca M. Pharmacokinetic-pharmacodynamic relationships of the anthracycline anticancer drugs. Clin Pharmacokinet 41 (2002) 431-444
106. Swain S.M., Whaley F.S., and Ewer M.S. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 97 (2003) 2869-2879
107. Kremer L.C., van Dalen E.C., Offringa M., Otten Kamp J., and Voute P.A. Anthracycline-induced clinical heart failure in a cohort of 607 children: long-term follow-up study. J Clin Oncol 19 (2001) 191-196
108. Paulides M., Kremers A., Stohr W., Bielack S., Jurgens H., Treuner J., et al. Prospective longitudinal evaluation of doxorubicin-induced cardiomyopathy in sarcoma patients: a report of the late effects of surveillance system. Pediatr Blood Cancer 46 (2006) 489-495
109. Pein F., Sakiroglu O., Dahan M., Lebidois J., Merlot P., Shamsaldin P., et al. Cardiac abnormalities 15 years and more after adriamycin therapy in 229 childhood survivors of a solid tumour at the Institute Gustaave Roussey. Br J Cancer 91 (2004) 37-44
110. Hequet O., Le Q., Moullet J., Pauli E., Salles G., Espinhouse D., et al. Subclinical late cardiomyopathy after doxorubicin therapy for lymphoma in adults. J Clin Oncol 22 (2004) 1864-1871
111. Salvetorelli E., Menna P., Cascegna S., Liberi G., Calafiore A.M., Gianni L., et al. Paclitaxel and docetaxel stimulation of doxorubicinol formation in the human heart: implications for cardiotoxicity of doxorubicin-taxane chemotherapies. J Pharmacol Exp Ther 318 (2006) 424-433
112. Herman E.H., Zhang J., Lipshulz S.E., Rifai N., Chadwick D., Takeda K., et al. Correlation between serum levels of cardiac troponin-T and the severity of the chronic cardiomyopathy induced by doxorubicin. J Clin Oncol 17 (1999) 2237-2243
113. Daugaard G., Lassen U., Bie P., Pederson R.B., Jansen K.T., Abidgaard U., et al. Naturetic peptides in the monitoring of anthracycline induced reduction in left ventricular ejection fraction. Eur J Heart Fail 7 (2005) 87-93
114. Lipshulz S.E., Giantris A.L., Lipsitz S.R., Kimball-Dalton V., Asselin B.L., Barr R.D., et al. Doxorubicin administration by continuous infusion is not cardioprotectant: the Dana-Farber 91-01 ALL protocol. J Clin Oncol 20 (2002) 1677-1682
115. Levitt G.A., Dorup I., Sorensen K., and Sullivan J. Does anthracycline administration by infusion in children affect late cardiotoxicity?. Br J Hematol 124 (2004) 463-468
116. Wiseman L.R., and Spencer C.M. Dexrazoxane. A review of its use as a cardio protective agent in patients receiving anthracycline-based chemotherapy. Drugs 56 (1998) 385-403
117. Lipshulz S.E., Rifai N., Dalton V.M., Levy D.E., Silverman L.B., Lipsitz S.R., et al. The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia. N Engl J Med 351 (2004) 145-153
118. Harris L., Batist G., Belt R., Rovira D., Navari R., Azarnia N., et al. Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma. Cancer 94 (2002) 25-36
119. Batist G., Ramakrishnan G., Rao C.S., Chandraskharan A., Gutheil J., Guthrie T., et al. Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. J Clin Oncol 19 (2001) 1444-1454
120. O'brien M.E., Wigler N., Imbar M., Rosso R., Santaro A., Grischke E., et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl versus conventional doxorubicin for the first line treatment of metastatic breast cancer. Ann Oncol 15 (2004) 440-449
121. Seboulli J., Oskay-Ozcelik G., Kuhne J., Stange P.D., Hindenberg H.J., Klare P., et al. Biweekly pegylated liposomal doxorubicin in patients with relapsed ovarian cancer: results of a multicenter phase-II trial. Ann Oncol 17 (2006) 957-961
122. Hui Y.F., and Cortes J.E. Palmar-plantar erythrodysesthesia syndrome associated with liposomal daunorubicin. Pharmacotherapy 20 (2000) 1221-1223
123. Uyar D., Kulp B., Peterson G., Markman M., and Belinson J. Cardiac safety profile of prolonged (> or <6 cycles) pegylated liposomal doxorubicin administration in patients with gynecologic malignancies. Gynecol Oncol 94 (2004) 147-151
124. Keefe D. Anthracycline-induced cardiomyopathy. Semin Oncol 28 s (2001) 2-4
125. Salvatorelli E., Guarnieri S., Menna P., Calatiori A.M., Marrigio H.A., Mordente A., et al. Defective one or two electron reduction of the anticancer agent epirubicin in human heart. J Biol Chem 281 (2006) 10990-11001
126. Ryberg M., Nielsen D., Skovsgaard T., Hansen J., Jensen B.V., and Dombernowsky P. Epirubicin cardiotoxicity: an analysis of 469 patients with metastatic breast cancer. J Clin Oncol 16 (1998) 3502-3508
127. Meinari M.T., van der Graaf W.T., Gietema J.A., Van den Berg M.P., Steijfer D.T., de Vries E.C., et al. Evaluation of long-term cardiotoxicity after epirubicin containing adjuvant chemotherapy and local regional radiotherapy for breast cancer using various detection techniques. Heart 88 (2002) 81-82
128. van Dalen E.C., Michiels E.M.C., Caron H.N., and Kremer L.C.M. Different anthracycline derivatives for reducing cardiotoxicity in cancer patients. Cochrane Data Syst Rev (2006) 4
129. Lipshulz S.E., Lipsitz S.R., Sallon S.E., Simbre V.C., Shaikh S.L., Mone S.M., et al. Long-term enalapril therapy for left ventricular dysfunction in doxorubicin-treated survivors of childhood cancer. J Clin Oncol 20 (2002) 4517-4522
130. Outomuro D., Grana D., Azzato R., and Milei J. Adriamycin induced myocardial toxicity: new solutions for an old problem?. Int J Cardiol 117 (2007) 6-15
131. Crump M., Tu D., Shepherd L., Levine M., and Bramwell V. Risk of acute leukemia following epirubicin-based adjuvant chemotherapy: a report from the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 21 (2003) 3066-3071
132. Praga C., Bergh J., Bliss J., Bonneterre J., Cesana B., Coomlies R.C., et al. Risk of acute myeloid leukemia and myelodysplastic syndrome in trials of adjuvant epirubicin for early breast cancer: correlation with doses of epirubicin and doxorubicin. J Clin Oncol 23 (2005) 4179-4191
133. Johnson S.A., and Richardson D.S. Anthracyclines in haematology: pharmacokinetics and clinical studies. Blood Rev 12 (1998) 52-71
134. Rudek M.A., Sparreboom A., Garrett-Mayer E.S., Armstrong D.K., Wolff A.C., Verweji J., et al. Factors affecting pharmacokinetic variability following doxorubicin and doxetaxel-based therapy. Eur J Cancer 40 (2004) 1170-1178
135. Li J., and Gwilt P.R. The effect of age on the early disposition of doxorubicin. Cancer Chemother Pharmacol 51 (2003) 395-402
136. Buganzoli L., Coleman R., Minisini A., Hamilton A., Aapro M., Therasse P., et al. A joint analysis of two EORTC studies to evaluate the role of pegylated doxorubicin (Caelyx) in the treatment of elderly patients with metastatic breast cancer. Crit Rev Oncol Hematol 61 (2007) 84-89
137. Gotlieb W.H., Bruchim I., Ben-Baruch G., Davidson B., Zettser A., Anderson A., et al. Doxorubicin levels in the serum and ascites of patients with ovarian cancer. Eur J Surg Oncol 33 (2007) 213-215
138. Samuel L., Cummings J., and Shaw P. Daunorubicin cardiotoxicity in childhood cancer. Lancet 352 (1998) 1150
139. Gabizon A., Shmeeda H., Barenholz Y., and Barenholz Y. Pharmacokinetics of pegylated liposomal doxorubicin: review of animal and human studies. Clin Pharmacokinet 42 (2003) 419-436
140. Waterhouse D.N., Tardi P.G., Mayer L.D., Bally M.B., et al. A comparison of liposomal formulations of doxorubicin with drug administered in free form. Drug Safety 24 (2001) 903-920
141. Mross K., Niemann B., Massing U., Drews J., Unger C., Bhamra R., et al. Pharmacokinetics of liposomal doxorubicin (TLC-D99;Myocet) in patients with solid tumors: an open-label, single dose study. Cancer Chemother Pharmacol 54 (2004) 514-524
142. Li Y., Finkel K.W., Hu W., Fu S., Liu J., Coleman R., et al. Pegylated liposomal doxorubicin treatment in recurrent gynecologic cancer patients with renal dysfunction. Gynecol Oncol 106 (2007) 375-380
143. Obyrne K.J., Thomas A.L., Sharma R.A., DeCartis M., Shields F., Beare S., et al. A phase I dose-escalating study of daunoxome, liposomal daunorubicin in metastatic breast cancer. Br J Cancer 87 (2002) 15-20
144. Belloff R., Auvrignon A., Leblanc T., Perel Y., Gandemer V., Bertrand Y., et al. Pharmacokinetics of liposomal daunorubicin (daunoxome) during a phase I-II study in children with relapsed leukemia. Cancer Chemother Pharmacol 47 (2001) 15-21
145. Danesi R., Conte P.F., and Del Tacca M. Pharmacokinetic optimization of treatment schedules for anthracyclines and paclitaxel in patients with cancer. Clin Pharmacokinet 37 (1999) 195-211
146. Grasselli G., Vigano L., Capri G., Locatelli A., Tarenzi E., Spreafico C., et al. Clinical and pharmacologic study of the epirubicin and paclitaxel combination in women with metastatic breast cancer. J Clin Oncol 19 (2001) 2222-2231
147. Innocenti F., Iyr L., Ramirez J., Green M.D., and Ratain M.J. Epirubicin glucuronidation is catalyzed by human UDP-glucuronyl-transferase 2B7. Drug Metab Dispos 29 (2001) 686-692
148. Zaya M.J., Hines R.N., and Stevens J.C. Epirubicin glucuronidation and UGT2B7 developmental expression. Drug Metab Dispos 34 (2006) 2097-2101
149. Gori S., Rulli A., Mosconi A.M., Sidoni A., Colozza M., and Crino L. Safety of epirubicin adjuvant chemotherapy in a breast cancer patient with chronic renal failure undergoing hemodialytic treatment. Tumori 92 (2006) 364-365
150. Hunz M., Jetter A., Warm M., Pantke E., Tuscher M., Hempel J., et al. Plasma and tissue pharmacokinetic of epirubicin and paclitaxel in patients receiving neoadjuvant chemotherapy for locally advanced breast cancer. Clin Pharmacol Ther 81 (2007) 659-668
151. Palle J., Frost B.M., Peterson C., Gustafsson B., Hellebostad D., Kanerva J., et al. Doxorubicin pharmacokinetics is correlated to the effect of induction therapy in children with acute myeloid leukemia. Anti-Cancer Drugs 17 (2006) 385-392
152. Hortobagyi G.N. Anthracyclines in the treatment of cancer. An overview. Drugs 54 Suppl. 4 (1997) 1-7
153. Lowenberg B., Downing J.R., and Burnett A. Acute myeloid leukemia. N Engl J Med 341 (1999) 1051-1062
154. Crivellari D., Lombardi D., Spazzapam S., Veronesi A., and Toffoli G. New oral drugs in older patients: a review of idarubicin in elderly patients. Crit Rev Oncol Hematol 49 (2004) 153-163
155. Freyer G., Lortholary A., Delcambre C., Delozier T., Pilot T., Genin F., et al. Unexpected toxicities in elderly patients treated with oral idarubicin in metastatic breast cancer. Clin Oncol 16 (2004) 17-23
156. Rivera E., Valero V., Arun B., Royce M., Adinin R., Hoelzer K., et al. Phase II study of pegylated liposomal doxorubicin in combination with gemcitabine in patients with metastatic breast cancer. J Clin Oncol 21 (2003) 3249-3254
157. Al-Batan S.E., Bischoff J., von Minckwitz G., Atmaca A., Kleeberg U., Meuthen I., et al. The clinical benefit of pegylated doxorubicin in patients with metastatic breast cancer previously treated with conventional anthracyclines: a multicentre phase II trial. Br J Cancer 94 (2006) 1615-1620
158. Caponigro F., Comella P., Bryce J., Avallone A., De Rosa V., Budillon A., et al. Phase I study of Caelyx (doxorubicin HCL, pegylated liposomal) in recurrent or metastatic head and neck cancer. Ann Oncol 11 (2000) 339-342
159. Mutch D.G., Orlando M., Goss T., Teneriello M.G., Gordon A.N., McMeekin S.D., et al. Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum resistant ovarian cancer. J Clin Oncol 25 (2007) 2811-2818
160. Hedenreich A., Sommer F., Ohlmann C., Schader A., Obert P., Goecke J., and Engelmann U.H. Prospective randomized phase II trial of pegylated doxorubicin in the management of symptomatic hormone-refractory prostate cancer. Cancer 101 (2004) 948-956
161. Samantas E., Kalofonos H., Linardou H., Nicolaides C., Mylonakis N., Fountzilas G., et al. Phase II study of pegylated liposomal doxorubicin: inactive in recurrent small-cell lung cancer. A Hellenic Cooperative Oncology Group Study. Ann Oncol 11 (2000) 1395-1397
162. Halm U., Etzrodt G., Schiefke I., Schmidt F., Witzigmann H., Mossner J., et al. A phase II study of pegylated liposomal doxorubicin for treatment of advanced hepatocellular carcinoma. Ann Oncol 11 (2000) 113-114
163. Muggia F.M., Blessing J.A., Sorosky J., and Reid G.C. Phase II trial of pegylated liposomal doxorubicin in previously treated metastatic endometrial cancer. A GOG study. J Clin Oncol 20 (2002) 2360-2364
164. Halford S., Yip D., Karapetic C.S., Strickland A.H., Steger A., Khawaja H.T., et al. A phase II study evaluating the tolerability and efficacy of CAELYX 1 liposomal doxorubicin, Doxill in the treatment of unresectable pancreatic carcinoma. Ann Oncol 12 (2001) 1399-1402
165. Thomas A.L., O'Byne K., Furber L., Jeffery K., Steward W., et al. A phase II study of calyx, liposomal doxorubicin: lack of activity in patients with advanced gastric cancer. Cancer Chemother Pharmacol 48 (2001) 266-268
166. Shields A.F., Lange L.M., and Zalupski M.M. Phase II study of liposomal doxorubicin in patients with advanced colorectal cancer. Am J Clin Oncol 24 (2001) 96-98
167. Otterson G.A., Villalona-Calero M.A., Sharma S., Kris M.G., Imondi A., Gerber M., et al. Phase I study of inhaled doxorubicin for patients with metastatic tumors to the lungs. Clin Cancer Res 13 (2007) 1246-1252
168. Faulds D., Balfour J.A., Chrisp P., and Langtry H.D. Mitoxantrone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer. Drugs 41 (1991) 400-449
169. Boland M.P., Fitzgerald K.A., and O'Neill L.A. Topoisomerase II is required for mitoxantrone to signal NFkB activation in HL60 cells. J Biol Chem 275 (2000) 25231-25238
170. Ferrer A., Marce S., Bellosillo B., Villamor N., Bosch F., Lopes-Guillermo A., et al. Activation of mitochondiral apoptotic pathway in mantel cell lymphoma: high sensitivity to mitoxantrone in cases with functional DNA-damage response genes. Oncogene 23 (2004) 8941-8949
171. Hazlehurst L.A., Foley N.E., Gleason-Guzman M.C., Hacker M.P., Cress A.E., Greenberger L.W., et al. Multiple mechanisms confer drug resistance to mitoxantrone in the human 8226 myeloma cell line. Cancer Res 59 (1999) 1021-1028
172. Allikmets R., Schriml L.M., Hutchinson A., Romano-Spica V., Dean M., et al. A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance. Cancer Res 58 (1998) 5337-5339
173. Scheffer G.L., Maliepaard M., Pijnenborg A.C., van Gastelen M.A., de Jong M.C., Schroeijers A.B., et al. Breast cancer resistance protein is localized at the plasma membrane in mitoxantrone- and topotecan-resistant cell lines. Cancer Res 60 (2000) 2589-2593
174. van den Heuvel-Eibrink M.M., Wiemer E.A., Prins A., Meijerink J.P., Vossebeld J.M., van der Holt B., et al. Increased expression of the breast cancer resistance protein (BCRP) in relapsed or refractory acute myeloid leukemia (AML). Leukemia 16 (2002) 833-839
175. Gupta A., Dai Y., Vethananayagam R.R., Hebert M.F., Thummel K.F., and Unadkat J.D. Cyclosporin A, tacrolimus and sirolimus are potent inhibitors of the human breast cancer resistance protein (ABCG2) and reverse resistance to mitoxantrone and topotecan. Cancer Chemother Pharmacol 58 (2006) 374-383
176. Zhang S., Yang X., and Morris M.E. Flavinoids are inhibitors of breast cancer resistance protein (ABCG2)-mediated transport. Mol Pharmacol 65 (2004) 1208-1216
177. Morrow C.S., Peklak-Scott C., Bishwokarma B., Kute T.E., Smitherman P.K., and Townsend A.J. Multi-drug resistance protein 1 (MRP1, ABCC1) mediates resistance to mitoxantrone via glutathione-dependent drug efflux. Mol Pharmacol 69 (2006) 1499-1505
178. Alberts D.S., Peng Y.M., Leigh S., Davis T.P., and Woodward D.L. Disposition of mitoxantrone in cancer patients. Cancer Res 45 (1985) 1879-1884
179. Ehninger G., Schuler U., Proksch B., Zeller K.P., and Blanz J. Pharmacokinetics and metabolism of mitoxantrone. A review. Clin Pharmacokinet 18 (1990) 365-380
180. LaCayo N.J., Lum B., Becton D.L., Weinstein H., Ravindranath Y., Chang M.N., et al. Pharmacokinetic interactions of cyclosporin with etoposide and mitoxantrone in children with acute myelogenous leukemia. Leukemia 16 (2002) 920-927
181. Posner L.E., Dukart G., Goldberg J., Bernstein T., and Cartwright K. Mitoxantrone: an overview of safety and toxicity. Invest New Drugs 3 (1985) 123-132
182. Ghalie R.G., Edan G., Laurent M., Mauch E., Eiseman S., Hartung H.F., et al. Cardiac adverse events associated with mitoxantrone therapy in patients with MS. Neurology 59 (2002) 909-913
183. van Dalen E.C., van der Pal H., Bakker P.J., Caron H., and Kremer L.C. Cummulative incidence and risk factors of mitoxantrone-induced cardiotoxicity in children: a systematic review. Eur J Cancer 40 (2004) 643-652
184. Le Deley M.C., Suzan F., Cutulli B., Delaloge S., Shamsaldin A., Linassier C., et al. Anthracyclines, mitoxantrone, radiotherapy and granulocyte colony-stimulating factor: risk factors for leukemia and myelodysplastic syndrome after breast cancer. J Clin Oncol 25 (2007) 292-300
185. Saso R., Kulkarni S., Mitchell P., Treleaven J., Swansbury G.J., Mehta J., et al. Secondary myelodysplastic syndrome/acute myeloid leukaemia following mitoxantrone-based therapy for breast carcinoma. Br J Cancer 83 (2000) 91-94
186. Ghalie R.G., Mauch E., Edan G., Hartung H.P., Gonsette R.E., Eisenmann S., et al. A study of therapy-related acute leukaemia after mitoxantrone therapy for multiple sclerosis. Mult Sclerosis 8 (2002) 441-445
187. Beaumont M., Sanz M., Carli P., Maloisel F., Thomas X., Detourmignies L., et al. Therapy-related acute promyelocytic leukemia. J Clin Oncol 21 (2003) 2123-2137
188. Mitstry A., Felix C., Whitmarsh B., Mason A., Reiter A., Cassinat B., et al. DNA topoisomerase II in therapy-related acute promyelocytic leukemia. N Engl J Med 352 (2005) 1529-1538
189. Cowan J.D., Neidhart J., McClure S., Coltman C.A., Gumbart C., Martino S., et al. Randomized trial of doxorubicin, bisantrene, and mitoxantrone in advanced breast cancer: a Southwest Oncology Group study. J Natl Cancer Inst 83 (1991) 1077-1084
190. Anderson J.E., Kopecky K.J., Willman C.L., Head D., O'Donnell M.R., Luthardt F.W., et al. Outcome after induction chemotherapy for older patients with acute myeloid leukemia is not improved with mitoxantrone and etoposide compared to cytarabine and daunorubicin: a Southwest Oncology Group study. Blood 100 (2002) 3869-3876
191. Wells R.J., Adams M.T., Alonzo T.A., Arceci J., Buckley J., Buxton A.B., et al. Mitoxantrone and cytarabine induction, high-dose cytarabine, and etoposide intensification for pediatric patients with relapsed or refractory acute myeloid leukemia: Children's Cancer Group Study 2951. J Clin Oncol 21 (2003) 2940-2947
192. Neuhaus O., Kieseier B.C., and Hartung H.P. Therapeutic role of mitoxantrone in multiple sclerosis. Pharmacol Ther 109 (2006) 198-209
193. Jensen L.H., Nitiss K.C., Rose A., Dong J., Zhou J., Hu T., et al. A novel mechanism of cell killing by anti-topoisomerase II bisdioxopiperazines. J Biol Chem 275 (2000) 2137-2146
194. Mizushina Y., Iida A., Ohta K., Sugawara F., and Sakaguchi K. Novel triterpenoids inhibit both DNA polymerase and DNA topoisomerase. Biochem J 350 (2000) 757-763
195. Etievant C., Kruczynski A., Barret J.M., Perrin D., van Hille B., Guminsky Y., et al. F 11782, a dual inhibitor of topoisomerases I and II with an original mechanism of action in vitro, and markedly superior in vivo antitumor activity, relative to three other dual topoisomerase inhibitors, intoplicin, aclarubicin and TAS-103. Cancer Chemother Pharmacol 46 (2000) 101-113
196. Byl J.A., Cline S.D., Utsugi T., Kobunai T., Yamada Y., Osheroff N., et al. DNA topoisomerase II as the target for the anticancer drug TOP-53: mechanistic basis for drug action. Biochemistry 40 (2001) 712-718
197. Ewesuedo R.B., Iyer L., Das S., Koenig A., Mani S., Vogelzang N.J., et al. Phase 1 clinical and pharmacogenetic study of weekly TAS-103 in patient with advanced cancer. J Clin Oncol 19 (2001) 2084-2090
198. Shinkre B.A., Raisch K.P., Fan L., and Velu SE. Analogs of the marine alkaloid makaluvamines: synthesis topoisomerase II inhibition and anticancer activity. Bioorg Med Chem Lett 17 (2007) 2890-2893
199. Bandele O.J., and Osheroff N. Bioflavonoids as poisons of human topoisomerase II alpha and II beta. Biochemistry 46 (2007) 6097-6108
200. Polycarpou-Schwarz M., Muller K., Denger S., Riddell A., Gannon F., et al. Thanatop: a novel 5-nitrofuran that is a highly active, cell-permeable inhibitor of topoisomerase II. Cancer Res 67 (2007) 4451-4458
201. Alousi A.M., Bionpally P., Wiegand R., Parchment R., Gadgeel S., Heilbrun L., et al. A phase 1 trial of XK469: toxicity profile of a selective topoisomerase II beta inhibitor. Invest New Drugs 25 (2007) 147-154
202. Gadelle D., Graille M., and Forterre P. The HSP90 and DNA topoisomerase VI inhibitor radicol also inhibits type II DNA topoisomerase. Biochem Pharmacol 72 (2006) 1207-1216
203. Geroni C., Ripamonti M., Arrigoni C., Fiorentini F., Capolongo L., Moneta D., et al. Pharmacological and toxicological aspects of 4-demethoxy-3-deamino-3-aziridinyl-4-methylsulphonyl-daunorubicin (PNU-159548): a novel antineoplastic agent. Cancer Res 61 (2001) 1983-1990
204. Pupa A., Landowshi T.H., and Dorr R.T. Ethonafide-induced cytotoxicity is mediated by topoisomerase II inhibition in prostate cancer cells. J Pharmacol Exp Ther 321 (2007) 1109-1117
205. Yusuke M., Hamada A., Okamoto I., Sasaki J., Moriyama E., Kishi H., et al. Pharmacokinetics of amrubicin and its active metabolite amrubicinol in lung cancer patients. Ther Drug Monit 28 (2006) 76-82